Vivo Bio Tech Ltd.

Your Drug Discovery Partner

Date: 11/02/2015

To
Deputy Manager
Dept. of Corporate Services,
Bombay Stock Exchange Limited
P J Towers, Dalal Street,
Fort, MUMBAI – 400001

Sub: Outcome of Board Meeting held on 11th February, 2015.

Ref: Script Code# 511509

With reference to subject cited above, we would like to inform you that the Directors met today i.e., 11th February, 2015 and transacted following business:

1. Approved the Un Audited Financial Results for Quarter ending on 31st December 2014.

We are herewith attaching the results sheet and Limited Review Report from Auditors of the company for the quarter ended 31st December 2014 pursuant Clause 41 of Listing agreement.

This is for your record and reference.

Thanking you,

Yours faithfully,

refer (0)

For Vivo Bio Federal

Whole Time Director

Registered Office: #608, 6th Floor, Lingapur Complex, Himayath Nagar, Hyderabad - 500029, Telangana, INDIA. Telephone: +91 - 40 - 2789 0662 - 5; Fax: +91 - 40 - 2789 0669 Address of Preclinical Research Facility: Vivo Bio Tech Special Economic Zone, Survey No. 349/A, Pregnapur - 502311, Gajwel Mandal, Medak District, Telangana, INDIA. Email: contact@vivobio.com Website: www.vivobio.com CIN No. L65993TG1987PLC007163

Vivo Bio Tech Ltd.

Your Drug Discovery Partner

-	Character .	(Douglast Co.	of Barrelone C. C.				Rs. In Lacs
	- Julement o	f Unaudited Financi	at Results for the	quarter ended on 3			10000000
S.No.			JARTER ENDED		NINE MONT	HS ENDED:	YEAR ENDEL
37.40	PARTICULARS	31-12-2014	30-09-2014	31-12-2013	31-12-2014	31-12-2013	31-03-2014
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income from Operations		The Desired			-	
	a) Net Sales/Income from Operations	464.40	349.43	453.24	1180.47	1206.65	
	b) Other Operating Income	0.00	0.00	0.00	0.00		1612.55
	Total Income from operations	464,40	349.43	The second secon		0.00	0.00
2	Expenses	404,40	349.43	453,24	1180.47	1206.65	1612.55
_	a. Increase/(decrease) in stock in trade and WIP						2000
		0.00	-14,20	0.00	-14.20	0.00	-26.31
	b. Consumption of Raw materials	94,77	68.44	0.67	234.13	203.70	294.97
	c. Purchase of traded goods	0.00	0.00	0.00	0.00	0.00	
	d. Employees Cost	104.05	53.67	70.37	212,32	156.23	222.80
	e. Depreciation	48.25	40.28	42.10	130.09	124.48	156.25
	f. Other Expenditure				0.00	124.40	130-23
	1.Administrative Expenditure	216.11	196.66	298,05			
	g. Total	463,19			637.77	643.20	946.14
	Profit/loss from Operations before other income,	963,19	344.84	411.19	1200.11	1157.61	1593.86
3	finance cost and exceptions items(1-2)	1.21	4.59	10.00	1-24/92	2560	(39509
4	Other income			42.04	-19.64	49.04	16.70
	Profit/(loss) from Ordinary activities before finance	20.92	19,46	18.00	62.88	59.25	88.29
5	costs and exceptional tiens(3+4)	22.13	24.04		F-1		
b	Finance costs	The second secon		60.04	43.24	108.29	106,99
	Profit / (loss) from Ordinary activities after finance	11.34	10.76	11.40	32.24	19,93	39.29
7	costs but before exceptional items(5-6)	10.79	13.70	1000	1000000	112	7000
5	Exceptional items		13.29	48.64	10.99	58.36	67.70
4		0.00	0.00	0.00	0.00	0.00	0.00
_	Profit/Loss from Ordinary Activities before tax(7-8)	10.79	13,29	48.64	10.99	88.36	67.70
10	Tax Experise	3.24	2.66	13.62	5.90	21.59	38.33
11	Net Profit/Loss from Ordinary Activities after Tax(9-10)	7.55	10.63	35.02	5.09	66.77	29.37
12	Estraordinary Items (Net of Tax expense of RsLakh)	0.00	0.00	0.00	0.00	0.00	
13	Not Profit/Loss for the Period(11-12)	7.55	10.63	35.02	5.09		0.00
14	Paid Up Share Capital(Face Value of Rs.10/-each)	935.05	935.05			66.77	19.37
	Reserves Excluding Revaluation Reserves as per	733/03	935.05	935.05	935.05	935.05	935.05
15	Balance sheet of previous accounting year	0.00	0.00	0.00	0.00		
16.1	Earning Per Share(EPS)(Before Extraordinary items)	0.00	0.00	0.00	0.00	0.00	0.06
	a)Basis	0.08		-			13.5
	hjDiluted		0.11	0.37	0.05	0.71	0.31
fi.o		0.08	0.11	0.37	0.05	0.71	0.31
n.a	Earning Per Share(EPS)(After Extraordinary items)						
	a) Basic	0.08	0.11	0.37	0.05	0.71	0.31
	b) Diluted	0.05	0.11	0.37	0.05	0.71	0.31
T-II-	Select Information for the Qtr and year ended on 31/12/20	14		300			1004
A.	Particulars of Shancholding						
1	Public Sharrholding						
	Number of Shares	2926437	202000	2007107			
	Percentage of Shareholding	A P A C A C C	2926437	2926437	2926437	2926437	2926437
	The second secon	31.30%	31.30%	31.30%	31,30%	31.30%	31,30%
2	Promoters and Promoter Group Shareholding						77/25
e .	Colored to compare on the colored to the colored to the						
- 1	a) Pledged/Encumbered						
	:Number of Shares	0	0	0	0	0	0,00
	Percentage of Shares					-	0.00
	(as a % of the total shareholding of promoter and						
	Control of the Contro	1000					
	Promoter Group)	0.00	0.00	0.00	0.00	0.00	0.00
	: Percentage of Shares				-	100	4100
	(as a % of the total sharecapital of the company)						
_	The state of the s	0	0	0	0	0	0.00
	b) Non-Encumbered					· ·	0.00
	:Number of Shares	6424083	6424083	6424083	4.131003		
	:Percentage of Shares	Grand)	0964003	.042408(3	6424083	6424083	6424083
	(as a % of the total shareholding of promoter and						
	Promoter Group)	Marie				a constant	
i i	Percentage of Shares	100%	100%	100%	100%	100%	100%
	Control of States						
	(as a % of the total sharecapital of the company)						
	the same of the sa	68.70%	68.70%	68,70%	44 704	77	1000000000
		DOL/12/A	08.7975	68.70%	68.70%	68 70%	68.70

The above results were reviewed by the Audit committee and appeared by the Board of Directors in their meeting held on 11th February 2015 and a limited review of the same has been carried out by the statutary auditors of the company

2 Status of complaints from the investors during the quarter ended 31st December, 2014 Pending 0 Nos Complaints Received -1 Nos., Complaints resolved -1 Nos., Complaints lying

3 The Standalone results are reviewed by the Statutory Auditors of the company in compiliance with clause 41 of Listing Agreement


The company Operates in Only one Segment
Previous Year's / Previous Period figures are regrouped/rearranged / recasted whe
Previous Year's / Previous Period figures are regrouped/rearranged / recasted whe

Place: Hyderabad Date: 11/02/2015

For VIVO BIO T M. Kalyan WHOLE TIME DO

Registered Office: #608, 6th Floor, Lingapur Complex, Himayath Nagar, Hyderabad - 500029, Telangana, INDIA. Telephone: +91 - 40 - 2789 0662 - 5; Fax: +91 - 40 - 2789 0669 Address of Preclinical Research Facility: Vivo Bio Tech Special Economic Zone, Survey No. 349/A, Pregnapur - 502311, Gajwel Mandal, Medak District, Telangana, INDIA. Email: contact@vivobio.com Website: www.vivobio.com

CIN No. L65993TG1987PLC007163



Tel. : (91-40) 2332 6666, 2331 2554

2339 3967, 2332 1470

Fax

: (91-40) 2339 2474 E-mail: pmurali.co@gmail.com

info@pmurali.com

Website: www.pmurali.com

To The Board of Directors M/s. Vivo Bio Tech Limited Hyderabad

Limited Review Report for the quarter ended 31st December 2014

We have reviewed the accompanying statement of unaudited financial results of M/s. Vivo Bio Tech Limited for the quarter ended 31st December 2014 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The company is in the process of reviewing the useful life of tangible fixed assets and identification of their major components, to enable it to provide depreciation on such assets in accordance with Schedule II of the Companies Act, 2013. Pending this, the depreciation on such assets has been provided for in accordance with Schedule XIV of the Companies Act, 1956. The effect to this is not quantified.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co. **Chartered Accountants**

red Ac

Place: Hyderabad

Date: 11th February 2015

Partner